Article info
PDFClinical science
Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen
- Correspondence to Dr Irmela Mantel, Jules Gonin Eye Hospital, Lausanne 1004, Switzerland; irmela.mantel{at}fa2.ch
Citation
Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen
Publication history
- Received April 17, 2018
- Revised July 7, 2018
- Accepted August 1, 2018
- First published August 30, 2018.
Online issue publication
June 21, 2019
Article Versions
- Previous version (21 June 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.